Balt
Paul Laquerre is currently serving as the Chief Financial Officer at Balt, a neurointerventional company with a complete portfolio. Prior to their current role, Paul held the same position at AgNovos Bioscience, a company developing treatments for osteoporosis, and at Seropeutics, LLC, a biopharmaceutical company targeting neuropsychiatric disorders. With experience at companies like Ameridose, Sperian Protection, and RecoveryCare, Paul has a strong background in finance and leadership. Paul also worked as a Finance Manager at Johnson & Johnson's DePuy Synthes division. Paul holds an MBA and a BS in Finance from Bryant University.
This person is not in any offices
Balt
1 followers
We are Balt. Physician-inspired innovations. Patient-focused solutions. For 45 years, Balt has been leading the way – collaborating with physicians and institutions to develop elegant neurovascular solutions. As the premier global neurovascular platform, always seeking to expand beyond boundaries, we are now bringing our innovation to the peripheral vascular space. We introduced the first neurovascular intervention device in 1977. Now, we offer the world’s broadest portfolio of medical devices for ischemic and hemorrhagic stroke, as well as devices for peripheral embolization. In 2015, we embarked on an ambitious journey and quadrupled our revenue and workforce, and that was only the beginning. Now, the Balt family includes more than 700 talented team members at 13 sites in 11 countries around the world. Be a part of our future: www.baltgroup.com